메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Colebrook Bosson Saunders Launches Their First Sustain…

HONG KONG, Nov. 21, 2025 -- As the world turns its attention to the environment during COP30, Colebrook Bosson Saunders (CBS), the leader in workplace ergonomics, is underscoring the need for collective action, transparency, and responsibility by the private sector. To support customers and the industry advance positive change, the brand released its first Sustainability Report this year, setting bold 2030 targets that demonstrate its commitment to responsible, forward-focused business. Access the Sustainability Report 2025 here: https://cdn.shopify.com/s/files/1/0788/7
- 김갑성 기자
- 2025-11-21 09:00
페프로민 바이오, BAFFR-CAR T 'PMB-CT01' 데이터, 2025년 ASH 제67차 연례학회 구…

어바인, 캘리포니아, 2025년 11월 21일 -- 재발•불응(r/r) B세포 악성 종양 치료를 위한 혁신 치료제를 개발하는 임상단계 바이오테크 기업 페프로민 바이오(PeproMene Bio, Inc.)가 자사 PMB-CT01(BAFFR-CAR T) 임상 1상 연구 초록 두 건이 2025년 미국혈액학회(American Society of Hematology, ASH) 연례학회에서 구두 발표로 채택됐다고 밝혔다. 해당 초록들은 고강도 사전 치료 이력이 있는 r/r B세포 급성 림프구성 백혈병(B-ALL) 및 r/r B세포 비호지킨 림프종(B-NHL) 환자를 대상으로 한 PMB-CT01의 초기 안전성 및 유효성 프로파일을 제시한다. 여기에는 기존 CD19 표적 치료에 실패했거나 CD19 음성 질환을 가진 환자도 포함된다. 임상 1상 단계적 용량증량 연구(NCT04690595, NCT05370430)의 중간 결과는 BAFF-R이 CD19 항원 소실을 극복하면서 내구성을 유지하고 독성이 낮은 차별화된 표적임을 시사한다. r/r B-NHL 안전성:PMB-CT01은 매우 우수한 내약성을 보였다. 1등급 초과의 사이토
- 김갑성 기자
- 2025-11-21 08:08
NABR: CITES 상임위원회, 긴꼬리원숭이 사육 실태 조사 결과 공개

워싱턴, 2025년 11월 21일 -- 동물종 거래 실태를 감시하는 국제기구인 CITES 상임위원회(CITES Standing Committee)가 과학적인 절차에 따라 방대한 자료를 제출한 캄보디아 정부에 사의를 표하면서 캄보디아의 동물 사육 방식에 대한 심사 결과를 발표했다. 차기 상임위원회 회의에 앞서 2025년 11월 12일에 발표된 이 보고서는 https://cites.org/eng/sc/79/agenda-documents에서 열람할 수 있다. 보고서는 몇 가지 긍정적인 조사 결과와 함께, 특히 캄보디아의 세관 및 검사 절차가 "국가 단일 창구 시스템을 통해 효과적으로 일원화 및 조정되었을 뿐 아니라, 검사와 문서화를 통해 투명성도 뒷받침한다"라고 기술하고 있다. 또한 보고서에서는 심사 과정 내내 보여준 "캄보디아의 개방성과 협조"에 찬사를 보내는 한편, "캄보디아가 입법 체계를 개선하고, 추적성을 강화하며, CITES 절차를 준수하려는 노력을 기울이고 있다"고 평가했다. 긴꼬리원숭이는 인간과 생물학적으로 매우 비슷해서, 전 세계 생물의학 연구에 꼭 필요한
- 김갑성 기자
- 2025-11-21 01:59
PeproMene Bio's PMB-CT01 BAFFR-CAR T Data Selected for Two O…

IRVINE, Calif., Nov. 20, 2025 -- PeproMene Bio, Inc., a clinical-stage biotechnology company developing novel therapies for relapsed and refractory (r/r) B-cell malignancies, announced that two abstracts from its ongoing Phase 1 studies of PMB-CT01 (BAFFR-CAR T) have been accepted for oral presentations at the 2025 American Society of Hematology (ASH) Annual Meeting. The abstracts showcase the emerging safety and efficacy profile of PMB-CT01 in heavily pretreated r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) and r/r B-cell Non-Hodgkin Lymphoma (B-NHL), including patients who
- 김갑성 기자
- 2025-11-20 23:12
HitGen Receives New Funding to Discover Novel Therapeutic…

Company enters into new agreement with the Gates Foundation to identify novel drug leads targeting tuberculosis and malaria and new agents for non-hormonal contraception. CHENGDU, China, Nov. 20, 2025 -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH), today announced that it has entered into a new contract agreement with the Gates Foundation. HitGen will leverage its industry-leading DNA-encoded library (DEL) platform to identify novel drug leads for the treatment of underserved diseases including tuberculosis and malaria, as well a
- 김갑성 기자
- 2025-11-20 22:30
GENPRIME ACCELERATES GLOBAL GROWTH WITH FERTILITY CENTRE LA…

The Singapore and New York-headquartered network of clinics expands its Southeast Asia presence, addressing global family-building challenges with technology and empathy NEW YORK, Nov. 20, 2025 -- Rhea Fertility, the reproductive health platform headquartered in Singapore and New York, announces the expansion of GenPrime, its clinic network, with the opening of two flagship fertility centres in Singapore and Manila, the Philippines. The launches mark a major step in scaling GenPrime's next-generation model of fertility care in Southeast Asia, helping couples and individuals pur
- 김갑성 기자
- 2025-11-20 22:00
ReviR Therapeutics Receives $4.6 Million CIRM Grant to Advanc…

BRISBANE, Calif., Nov. 20, 2025 -- ReviR Therapeutics, a biotech company focused on developing innovative treatments for neurogenetic diseases, announced today that it has been awarded a $4.6M grant from the California Institute for Regenerative Medicine (CIRM), and has recently reached a key program milestone, having identified a lead compound that meets key development criteria. This funding will further support the advancement of ReviR Therapeutics' HTT-PMS1 genetic medicine program, whereby a small molecule selectively reduces the mRNA of two genes implicated in both the cause and progres
- 김갑성 기자
- 2025-11-20 22:00
Kolmar Korea Named Among TIME's World's Best Companies…

Ranked in the Top 7% Among More Than 4,000 Global Corporations, Highlighting Leadership in Eco-Friendly Innovation and Responsible Growth SEOUL, South Korea, Nov. 20, 2025 -- Kolmar Korea, a global cosmetics ODM leader, has been selected for the second consecutive year to TIME's World's Best Companies in Sustainable Growth 2026, reaffirming its position as a global front-runner in eco-friendly and responsible business practices. The rankings were announced on November 13 by TIME in collaboration with global research firm Statista, recognizing the top 500 companies worldwide for
- 김갑성 기자
- 2025-11-20 21:30
Henlius' Serplulimab (anti-PD-1 mAb) Granted Breakthrough Th…

[ 메디채널 김갑성 기자 ] The first CDE-designated Breakthrough Therapy for perioperative gastric cancer, promising accelerated patient access. The world's first gastric cancer perioperative regimen replacing chemotherapy with immunotherapy alone in the adjuvant setting has met primary endpoints in its phase 3 clinical trial, significantly reducing recurrence risk and improving cure rates. No immunotherapy has been approved globally for gastric cancer perioperative treatment – HANSIZHUANG is poised to address this unmet medical need. SHANGHAI, Nov. 20, 2025 -- Shanghai Henlius Biotech,
- 김갑성 기자
- 2025-11-20 18:52
Clarity Eye Centre Brings SILK™ Laser Eye Technology to Hon…

HONG KONG, Nov. 20, 2025 -- Clarity Eye Centre announced the arrival of Johnson & Johnson's next-generation SILK™ Laser Eye Technology, now available to patients in Hong Kong. The clinic is the first in the city to widely offer the ELITA™ Femtosecond Laser, the advanced system that powers SILK™ (Smooth Incision Lenticule Keratomileusis), ushering in a new era of precision and gentle laser vision correction for myopia, with or without astigmatism.[1] SILK™: A Revolutionary Leap in Refractive Surgery SILK™ represents a groundbreaking advancement in vision
- 김갑성 기자
- 2025-11-20 17:34

이전

21 22 23 24 25 26 27 28 29 30

많이 본 기사

최근기사

2025-12-10_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 10일 21시 20분